<html><body><h2>Case: 1016579</h2><h3> CDS Time: 1967-11-23</h3>
<patient name=1016579>
67.0 year old Asian_or_Pacific-Islander_Non-Hispanic Male
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">67</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">0</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Calcium</td><td width="200">7</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">55</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Phosphorus</td><td width="200">11</td><td width="200">1967-10-28</td></tr>
<tr><td width="200">Potassium</td><td width="200">4</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Chloride</td><td width="200">102.0</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">35</td><td width="200">1967-9-28</td></tr>
<tr><td width="200">BUN</td><td width="200">23</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">HGB</td><td width="200">8</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">HCT</td><td width="200">26</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Sodium</td><td width="200">139</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Albumen</td><td width="200">2</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Creatinine</td><td width="200">5.8</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Weight</td><td width="200">170</td><td width="200">1967-9-28</td></tr>
<tr><td width="200">HbA1C</td><td width="200">7</td><td width="200">1967-9-29</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">7</td><td width="200">1967-9-29</td></tr>
<tr><td width="200">SGOT</td><td width="200">235</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Pulse</td><td width="200">88</td><td width="200">1967-9-28</td></tr>
<tr><td width="200">PLT</td><td width="200">309</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">WBC</td><td width="200">7</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">84</td><td width="200">1967-9-28</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">1967-10-12</td></tr>
<tr><td width="200">SGPT</td><td width="200">152</td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Atrial_Tachycardia</td><td width="200"></td><td width="200">1967-9-28</td></tr>
<tr><td width="200">Nephritis_nephrosis_renal sclerosis</td><td width="200"></td><td width="200">1967-10-17</td></tr>
<tr><td width="200">cardiac arrest</td><td width="200"></td><td width="200">1967-10-13</td></tr>
<tr><td width="200">Liver_Disease</td><td width="200"></td><td width="200">1967-10-13</td></tr>
<tr><td width="200">Occulusion of cerebral arteries</td><td width="200"></td><td width="200">1967-10-22</td></tr>
<tr><td width="200">DM-Type2</td><td width="200"></td><td width="200">1967-10-12</td></tr>
<tr><td width="200">Atrial_Fibrillation</td><td width="200"></td><td width="200">1967-10-2</td></tr>
<tr><td width="200">Renal disease</td><td width="200"></td><td width="200">1967-10-29</td></tr>
<tr><td width="200">CKD</td><td width="200"></td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1967-10-1</td></tr>
<tr><td width="200">Renal_Insufficiency</td><td width="200"></td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Sex</td><td width="200">Male</td><td width="200"></td></tr>
<tr><td width="200">Diabetes with renal manifestations</td><td width="200"></td><td width="200">1967-10-9</td></tr>
<tr><td width="200">End-Stage_Renal_Disease</td><td width="200"></td><td width="200">1967-10-29</td></tr>
<tr><td width="200">Race</td><td width="200">Asian_or_Pacific-Islander_Non-Hispanic</td><td width="200"></td></tr>
</table>
<p><b>Medications:</b> aspirin(81.0) labetalol(60.0) hydralazine(0.0) Insulin(0.01) amiodarone(1.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Renal_insufficiency_w_creat>=2.1</td>
<td width="200"></td>
<td width="200"> Renal Insufficiency[Creatinine(5.8/1967-10-29)]()</td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of cerebral vascular dx]()</td></tr>
<tr><td width="200">On Amiodarone</td>
<td width="200"></td>
<td width="200"> Amiodarone[amiodarone]()</td></tr>
<tr><td width="200">DM (2ary prev)  BP controlled</td>
<td width="200"></td>
<td width="200"> Diabetes (Secondary Prevention)[Treatment_Diastolic_BP(35/null) && Treatment_Systolic_BP(84/null) && presence of diabetes mellitus]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[Age(67.0/1970-1-1) && Sex(Male)]()</td></tr>
<tr><td width="200">CKD by eGFR or ICD9 codes</td>
<td width="200"></td>
<td width="200"> CKD[presence of CKD (icd9 codes)]()</td></tr>
<tr><td width="200">Age > 65</td>
<td width="200"></td>
<td width="200"> age > 65 years[Age(67.0/1970-1-1)]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">taking >= 2 anti hypertensive meds</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Renal-Urinary_Diseases</td>
<td width="200">1967-10-17</td>
<td width="200"> Nephritis_nephrosis_renal sclerosis()</td></tr>
<tr> <td width="200"></td>
<td width="200">1967-10-29</td>
<td width="200"> CKD()</td></tr>
<tr> <td width="200"></td>
<td width="200">1967-10-29</td>
<td width="200"> Renal_Insufficiency()</td></tr>
<tr> <td width="200"></td>
<td width="200">1967-10-29</td>
<td width="200"> Renal disease()</td></tr>
<tr><td width="200">Hepatobiliary_Diseases</td>
<td width="200">1967-10-13</td>
<td width="200"> Liver_Disease()</td></tr>
<tr><td width="200">CCS-7.4</td>
<td width="200">1967-10-22</td>
<td width="200"> Occulusion of cerebral arteries()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">1967-10-02</td>
<td width="200"> Atrial_Fibrillation()</td></tr>
<tr> <td width="200"></td>
<td width="200">1967-09-28</td>
<td width="200"> Atrial_Tachycardia()</td></tr>
<tr> <td width="200"></td>
<td width="200">1967-10-13</td>
<td width="200"> cardiac arrest()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">1967-10-01</td>
<td width="200"> Hypertension()</td></tr>
<tr><td width="200">Endocrine_Diseases</td>
<td width="200">1967-10-12</td>
<td width="200"> DM-Type2()</td></tr>
<tr> <td width="200"></td>
<td width="200">1967-10-09</td>
<td width="200"> Diabetes with renal manifestations()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200">1967-10-29</td>
<td width="200"> End-Stage_Renal_Disease()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
</table><p>
</patient>
<h1 align="center">VA/JNC-VII Hypertension Guideline</h1>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(presence of diagnosis of hypertension && absence of renovascular disease && no diagnosis of pregnancy && Absense of Secondary Hypertension && absence of spinal cord injury && absence of narcolepsy && Not taking cyclosporine && Not taking spironolactone && Not taking minoxidil && absence of renovascular disease && absence of IHSS && Absence of Ascites && Not off guideline && not taking tacrolimus && absence of transplant recipient && Absence of a dialysis procedure code)</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(presence of DM)</i>]
</ul>
<b>Scenario choice:</b> on two or three anti-hypertensive drugs
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(35/null) && Treatment_Systolic_BP(84/null))
<p><b>Messages by Types</b>
<ul>
<li><b>Recommendation</b>
<ul>
<li>Warning: creatinine value is greater than 1.5 mg/dL, upper limit of normal for males.
<li>Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
<li>It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: labetalol, Insulin, hydralazine, amiodarone
<li>The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>Assumption</b>
<ul>
<li>We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>on medication: things to check</b><br>
<ul>
<li><b>assumption  check presence of BP <font color=FF0000>preferred</font></b>(rule in criterion<i> diastolic BP or systolic BP absent</i> evaluate to <b> true</b> because <i>absence of diastolic BP</i>)])
We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
<li><b>creatinine > ULN, check creatinine <font color=FF0000>preferred</font></b>(rule in criterion<i> creatinine > upper limit of normal</i> evaluate to <b> true</b> because <i>Creatinine(5.8/1967-10-29)</i>)])
Warning: creatinine value is greater than 1.5 mg/dL, upper limit of normal for males.
<li><b>adverse event warning <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of current medication with adverse reaction</i> evaluate to <b> true</b> because <i>presence of current medication with adverse reaction</i>)])
<li><b>Beta blocker and diabetes <font color=FF0000>preferred</font></b>(rule in criterion<i> On beta blocker and DM</i> evaluate to <b> true</b> because <i>presence of DM && beta blocker being used</i>)])
Beta blockers may mask symptoms of hypoglycemia and should be used with caution.
<li><b>Liver Disease and Labetalol <font color=FF0000>preferred</font></b>(rule in criterion<i> Liver Disease and Labetalol</i> evaluate to <b> true</b> because <i>Presence of liver disease && Taking labetalol</i>)])
Labetalol has extensive first pass clearance and the rate of metabolism is sensitive to hepatic blood flow. Liver disease is a relative contraindication.
<li><b>On beta blocker hyperlipidemia <font color=FF0000>preferred</font></b>(rule in criterion<i> beta blocker being used</i> evaluate to <b> true</b> because <i>beta blocker being used</i>)])
Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
<li><b>test parameterized message <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: labetalol, Insulin, hydralazine, amiodarone
<li><b>Disclaimer <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>two or three drug-therapy choices</b><br>
<ul>
<li><b>continue with two or three drug regimen <font color=FF0000>preferred</font></b>(strict rule-in condition<i> (~B & A &~E) cannot do better</i> evaluate to <b> true</b> because <i>(~B)no current drug contraindicatedthere exists a contraindicated current med && Treatment_Diastolic_BP(35/null) && Treatment_Systolic_BP(84/null) && (~E)no (compellingly indicated not given and current drug not indicated)there exists a non-betablocker, non-ACE, non-clonidine , non (alpha blocker + BPH)drug to replace</i>)])
Most recent Systolic BP in database is less than 100. Use your clinical judgment about safety of  adding, substituting, or maintaining drug regimen.
</ul>
</ul>
</body></html>